CORCEPT THERAPEUTICS INC CORT

expiry = 2021-12-07...cs Incorporated Up to 10,000,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $23.75 per Share Nor Less than $20.75 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON DECEMBER 7, 2021, UNLESS THE OFFER IS EXTENDED OR TERMINATED (SUCH DATE AND TIME, AS THEY MAY BE EXTENDED, THE “EXPIRATION DATE”). The undersigned represents that I (we) have full authority to tender without restriction the Shares (as defined herein) liste...

mechanism = FIXED...December 15, 2021. Based on the preliminary count by Continental Stock Transfer & Trust Company, the depositary for the Tender Offer (the “Depositary”), 31,743,651 shares of Corcept’s common stock were validly tendered and not properly withdrawn at or below a purchase price of $23.75 per share, including 13,648,561 shares tendered by notice of guaranteed delivery. In accordance with the terms and conditions of the Tender Offer, and based on the preliminary results reported by the Depositary, Corcept expects to purchase approximately 10,000,000 shares of common stock at a purchase price of $20.75 per share, for an aggregate cos...

mechanism = FIXED...ed pursuant to Rule 13e-4(c)(4): • The Company has received the final results of the Offer, which expired one minute after 11:59 p.m., New York City time, on December 15, 2021. • The Company has accepted for purchase 10,000,000 shares of its common stock at a purchase price of $20.75 per share, for an aggregate purchase price of $207,500,000, excluding fees and expenses relating to the Offer. The number of shares of common stock that the Company has accepted for purchase in the Offer represents approximately 9% of the total number of shares of common stock outstanding as of December 15, 2021. • Due to the oversubscription of t...

must_tender_all = True...d in Section 1 of the Offer to Purchase, if the Company is to purchase fewer than all Shares properly tendered before the Expiration Date and not properly withdrawn, Shares purchased first will consist of all Odd Lots of less than 100 Shares from stockholders who validly tender all of their Shares at or below the Final Purchase Price and who do not validly withdraw them before the Expiration Date. Tenders 17 of less than all of the Shares owned, beneficially or of record, by such Odd Lot Holder will not qualify for this preference. This preference will not be available unless the section captioned “Odd Lots” in this Letter of Tran...

price = USD 23.75...& Trust Company, the depositary for the Tender Offer (the “Depositary”), 31,743,651 shares of Corcept’s common stock were validly tendered and not properly withdrawn at or below a purchase price of $23.75 per share, including 13,648,561 shares tendered by notice of guaranteed delivery. In accordance with the terms and conditions of the Tender Offer, and based on the preliminary results reported by the Depositary, Corcept expects t...

price = USD 20.75...the Offer, which expired one minute after 11:59 p.m., New York City time, on December 15, 2021. • The Company has accepted for purchase 10,000,000 shares of its common stock at a purchase price of $20.75 per share, for an aggregate purchase price of $207,500,000, excluding fees and expenses relating to the Offer. The number of shares of common stock that the Company has accepted for purchase in the Offer represents approximately...

txn_type = TENDER_OFFEREX-99.(A)(1)(B) 3 d228455dex99a1b.htm EX-(A)(1)(B) EX-(a)(1)(B) EXHIBIT (a)(1)(B) Letter of Transmittal For Tender of Shares of Common Stock Pursuant to the Offer to Purchase, Dated November 8, 2021 by Corcept Therapeutics Incorporated Up to 10,000,000 Shares of its Common Stock At a Cash Purchase Price Not Greater than $23.75 per Share Nor Less than $20.75 per Share THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE (1) MINUTE AFTER 11:59 P.M., NEW YORK CITY TIME, ON DECEMBER 7, 2021, UNLES...

txn_type = TENDER_OFFER...pt”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the preliminary results of its previously announced tender offer to purchase up to 10,000,000 shares of its common stock, par value $0.001 per share, at a price not greater than $23.75 nor less than $20.75 per share, in cash, less any applicable withholding taxes and without interest (the “Tender Offer”), which expired one minute after 11:59 p.m., New York City time, on December 15, 2021. Based on the preliminary...

txn_type = TENDER_OFFER...s Amendment, the “Schedule TO”), which relates to the offer by the Company to purchase up to 10,000,000 shares of its common stock, par value $0.001 per share (the “Shares”), at a price not greater than $23.75 nor less than $20.75 per Share, as defined in the Offer to Purchase (defined below), in cash, less any applicable withholding taxes and without interest. The Company’s offer was made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated November 8, 2021 (together with any amendments or supplements thereto, including Amendment No. 1 and Amendment No. 2, the “Offer to Purch...

accepted = 10000000...rovided pursuant to Rule 13e-4(c)(4): • The Company has received the final results of the Offer, which expired one minute after 11:59 p.m., New York City time, on December 15, 2021. • The Company has accepted for purchase 10,000,000 shares of its common stock at a purchase price of $20.75 per share, for an aggregate purchase price of $207,500,000, excluding fees and expenses relating to the Offer. The number of shares of common stock that the Company has accepted for purchase in the Offer represents approximately...

final_price = 20.75...ived the final results of the Offer, which expired one minute after 11:59 p.m., New York City time, on December 15, 2021. • The Company has accepted for purchase 10,000,000 shares of its common stock at a purchase price of $20.75 per share, for an aggregate purchase price of $207,500,000, excluding fees and expenses relating to the Offer. The number of shares of common stock that the Company has accepted for purchase in the Offer represents approximately 9% of the total number of shares of common stock outstanding...